Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5718207 | 1.00 | MAPT (0.40) | MAPTMAPK1NPSR1L3MBTL1SLC6A4 | |
| SCHEMBL5718307 | 0.85 | MAPT (0.42) | MAPTMAPK1NPSR1L3MBTL1SLC6A4 | |
| SCHEMBL5718303 | 0.85 | MAPT (0.42) | MAPTMAPK1NPSR1L3MBTL1SLC6A4 | |
| SCHEMBL5718228 | 0.83 | MAPT (0.40) | MAPTMAPK1NPSR1L3MBTL1SLC6A4 | |
| SCHEMBL5718243 | 0.83 | HSD17B10 (0.47) | MAPTMAPK1NPSR1L3MBTL1ALDH1A1 | |
| SCHEMBL5718373 | 0.83 | MAPT (0.41) | MAPTMAPK1NPSR1L3MBTL1SLC6A4 | |
| SCHEMBL5718355 | 0.80 | HRH3 (0.35) | MAPTKMT2A | |
| SCHEMBL29519179 | 0.79 | SLC6A3 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL18939593 | 0.78 | SLC6A3 (0.57) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1856262 | 0.77 | SLC6A3 (0.60) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141560-B2 | Alanine 2,6-dialkoxyphenyl ester derivatives as hypnotics | AKZO NOBEL N.V. (NL) | 2006-11-28 | — | — | US | disclosed |
| EP-1373188-B1 | ALANINE 2,6-DIALKOXYPHENYL ESTER DERIVATIVES AS HYPNOTICS | AKZO NOBEL NV (NL) | 2006-06-07 | — | — | EP | disclosed |
| US-20040059109-A1 | Alanine 2, 6-dialkoxyphenyl ester derivatives as hypnotics | N.V. ORGANON (NL) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059109-A1 | Alanine 2, 6-dialkoxyphenyl ester derivatives as hypnotics | OPRM1, OPRD1, OPRK1 | MAPT 3815/4885MAPK1 2206/4885NPSR1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.